Loading stock data…
Edgewise Therapeutics, Inc. (EWTX)
$40.92-0.54 (-1.30%)
After Hours$40.92+0.00 (+0.00%)· Last close Jun 29
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Edgewise Therapeutics, Inc. in the Healthcare sector is trading at $40.92 with a market capitalization of $3.7B. Wall Street consensus targets $48.17 (12 analysts), implying a +17.7% move over the next 12 months. The stock is currently near its 52-week high of $43.93, remaining 53.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +17.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$54.12M↑ | -$55.98M↓ | -$46.86M↓ | -$42.61M↑ | -$45.96M |
| Net Income | -$49.01M↑ | -$50.22M↓ | -$40.67M↓ | -$36.12M↑ | -$40.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.69%
Volume
Today's trading volume
1.87M
Recent News
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?
Is EWTX a good stock to buy? We came across a bullish thesis on Edgewise Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on EWTX. Edgewise Therapeutics, Inc.’s share was trading at $38.83 as of June 23rd. Edgewise Therapeutics is positioned as a high-conviction clinical-stage biotech transitioning into a substantially […]
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the best healthcare stocks. TheFly reported on June 17 that RBC Capital increased its price target for EWTX to $59 from $48 while maintaining an Outperform rating on the shares. The firm […]
Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says
Edgewise Therapeutics (EWTX) remains a compelling cardiology story despite investor concerns around
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?
Edgewise Therapeutics shares yo-yoed Tuesday as investors compared the results of its experimental heart disease treatment to approved drugs.
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial. Patients received doses ranging from 25 mg to 150 mg. EDG-7500 demonstrated clinically meaningful improvements in patients with both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). HCM is a genetic heart condition where the heart muscle thickens, making it harder for the heart to pump blood and potentially leading to complications like hea